Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cellectar Biosciences Inc

CLRB
Current price
2.5 USD -0.06 USD (-2.34%)
Last closed 2.57 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 31 580 930 USD
Yield for 12 month +35.14 %
Week
Month
Year
CLRB
21.11.2021 - 28.11.2021

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. Address: 100 Campus Drive, Florham Park, NJ, United States, 07932

Analytics

WallStreet Target Price

12.6 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures CLRB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -33 674 728 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -103.48 %
PEG Ratio
Return On Equity TTM -435.97 %
Wall Street Target Price 12.6 USD
Revenue TTM
Book Value -1.49 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -3.26 USD
Diluted Eps TTM -3.26 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CLRB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CLRB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 22.07.2022
Dividend Date 17.07.2018

Stock Valuation CLRB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.4319
Price Book MRQ 2.6673

Financials CLRB

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CLRB

For 52 weeks

1.25 USD 3.15 USD
50 Day MA 2.44 USD
Shares Short Prior Month 861 843
200 Day MA 1.9 USD
Short Ratio 5.35
Shares Short 800 113
Short Percent 8.08 %